Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Manfidokimab (AK120) in Healthy Subjects and Atopic Dermatitis
NCT04256174Phase 1Completed
- Sponsor
- Akeso, Inc.
- Start
- Jun 2020
- Primary completion
- Oct 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of manfidokimab in atopic dermatitis (AD) (9 arms), sponsored by Akeso, Inc. Primary endpoint: Adverse events (AEs)/serious adverse events (SAEs). Started Jun 2020; status: completed.
02
Drugs
manfidokimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04256174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04256174.